指南与共识呼吸衰竭与机械通气

免疫实践咨询委员会关于使用二价COVID-19疫苗加强针的临时推荐——美国,2022年10月

Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
指南 / 共识 · MMWR Morb Mortal Wkly Rep · 2022-11-11
一句话结论ACIP与CDC推荐所有≥5岁人群在完成任何单价基础免疫或单价加强针≥2个月后接种1剂二价mRNA加强针。

美国FDA于2022年9-10月修订紧急使用授权,允许≥5岁、已完成任何FDA批准或授权单价基础免疫者使用二价mRNA疫苗加强,并撤销单价COVID-19加强针的紧急使用授权。辉瑞-BioNTech与Moderna二价加强针各含等量祖先株与Omicron BA.4/BA.5株刺突mRNA。此后ACIP与CDC推荐所有≥5岁人群在完成任何FDA批准或授权的单价基础免疫或单价加强针≥2个月后接种1剂二价mRNA加强针。此举针对Omicron变异株(B.1.1.529)流行期间COVID-19疫苗有效性下降,旨在提高加强针保护力。

要点

  • ACIP与CDC推荐所有≥5岁人群接种1剂二价mRNA加强针。
  • 接种时机为完成任何FDA批准或授权的单价基础免疫或单价加强针≥2个月后。
  • 辉瑞-BioNTech与Moderna二价加强针各含等量祖先株与Omicron BA.4/BA.5株刺突mRNA。
  • FDA已撤销单价COVID-19加强针的紧急使用授权。
  • 二价加强针旨在应对Omicron变异株(B.1.1.529)流行期间疫苗有效性下降。

适用人群与场景

  • ≥5岁、已完成任何FDA批准或FDA授权的单价COVID-19基础免疫或单价加强针的人群。

处置流程与药物剂量

  • 所有≥5岁人群在完成任何FDA批准或FDA授权的单价基础免疫或单价加强针≥2个月后接种1剂二价mRNA加强针(ACIP与CDC推荐)。

研究设计与关键结果

  • 2022年9-10月,FDA授权二价mRNA疫苗用于≥5岁、已完成任何FDA批准或FDA授权基础免疫者的加强接种,并撤销单价COVID-19加强针的紧急使用授权。
  • 辉瑞-BioNTech与Moderna二价加强针各含等量祖先株与Omicron BA.4/BA.5株刺突mRNA。
  • ACIP与CDC推荐所有≥5岁人群在完成任何FDA批准或FDA授权的单价基础免疫或单价加强针≥2个月后接种1剂二价mRNA加强针。

证据类型、等级与局限

  • 证据类型:免疫实践咨询委员会(ACIP)临时推荐(指南)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • ≥5岁、已完成任何FDA批准或FDA授权单价基础免疫或单价加强针≥2个月者,按ACIP与CDC推荐接种1剂二价mRNA加强针。
  • 单价COVID-19加强针的紧急使用授权已被FDA撤销。

指南或共识出处

  • 《免疫实践咨询委员会关于使用二价COVID-19疫苗加强针的临时推荐——美国,2022年10月》,MMWR Morb Mortal Wkly Rep。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Four COVID-19 vaccines are currently approved for primary series vaccination in the United States under a Biologics License Application or authorized under an emergency use authorization (EUA) by the Food and Drug Administration (FDA), and recommended for primary series vaccination by the Advisory Committee on Immunization Practices (ACIP): 1) the 2- or 3-dose monovalent mRNA BNT162b2 (Pfizer-BioNTech, Comirnaty) COVID-19 vaccine; 2) the 2- or 3-dose monovalent mRNA mRNA-1273 (Moderna, Spikevax) COVID-19 vaccine; 3) the single-dose adenovirus vector-based Ad26.COV.S (Janssen [Johnson & Johnson]) COVID-19 vaccine; and 4) the 2-dose adjuvanted, protein subunit-based NVX-CoV2373 (Novavax) COVID-19 vaccine. The number of doses recommended is based on recipient age and immunocompromise status (1). For additional protection, FDA has amended EUAs to allow for COVID-19 booster doses in eligible persons (1). Because COVID-19 vaccines have demonstrated decreased effectiveness during the period when the Omicron variant (B.1.1.529) of SARS-CoV-2 predominated, bivalent booster doses (i.e., vaccine with equal components from the ancestral and Omicron strains) were considered for the express purpose of improving protection conferred by COVID-19 vaccine booster doses (2). During September-October 2022, FDA authorized bivalent mRNA vaccines for use as a booster dose in persons aged ≥5 years who completed any FDA-approved or FDA-authorized primary series and removed EUAs for monovalent COVID-19 booster doses (1). Pfizer-BioNTech and Moderna bivalent booster vaccines each contain equal amounts of spike mRNA from the ancestral and Omicron BA.4/BA.5 strains. After the EUA amendments, ACIP and CDC recommended that all persons aged ≥5 years receive 1 bivalent mRNA booster dose ≥2 months after completion of any FDA-approved or FDA-authorized monovalent primary series or monovalent booster doses.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

参考来源

  1. Rosenblum HG, Wallace M, Godfrey M, et al. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36355612. doi:10.15585/mmwr.mm7145a2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。